β2-adrenoceptor activation modulates skin wound healing processes to reduce scarring

Area of Science:

• Dermatology and Regenerative Medicine
• Wound Healing and Scarring Research

Background:

• Scarring affects over 100 million patients annually, with excessive inflammation, angiogenesis, and fibroblast function contributing to poor scar quality.
• Hyperpigmentation also negatively impacts the cosmetic outcome of scars.
• The role of the beta 2 adrenergic receptor (β2AR) in modulating these scarring processes remains to be fully elucidated.

Purpose of the Study:

• To investigate the potential of beta 2 adrenergic receptor agonists (β2ARag) in reducing scar formation and improving scar quality.
• To explore the mechanisms by which β2ARag influences human dermal fibroblast (HDF) differentiation and function.
• To assess the impact of β2ARag on wound inflammation, angiogenesis, and scarring in various preclinical models.

Main Methods:

• Exploration of β2ARag effects on HDF differentiation and function in vitro.
• Assessment of β2ARag's impact on inflammation in zebrafish and angiogenesis in the chick chorioallantoic membrane (CAM) assay.
• Evaluation of β2ARag treatment in a Red Duroc pig full-thickness skin wound model.

Main Results:

• β2ARag significantly reduced HDF differentiation and contractile function, inhibiting profibrotic marker expression.
• In vivo studies demonstrated that β2ARag reduced inflammation in zebrafish and angiogenesis in CAM assays.
• In porcine models, β2ARag treatment decreased scar area and hyperpigmentation by nearly 50%, markedly improving scar quality by modulating macrophage infiltration and angiogenesis.

Conclusions:

• The study identifies a β2AR-mediated mechanism for scar reduction.
• β2ARag demonstrates significant potential in improving skin scarring by reducing key pathological processes.
• These findings suggest β2ARag as a promising therapeutic agent for enhancing wound healing and minimizing scar formation.